TB cash flow to countries through Global Fund grants, July- August 2013

In the first eight months of 2013, countries received a little over US$ 2 billion for the three diseases, of which US$ 402 million was allocated to TB. This equals 21% of the two-year funding envelope for TB.

In the past two months – July and August, 37 countries received US$ 119 million of cash disbursements to TB grants. The largest disbursements were made to Ethiopia (US$ 18.6 million), Pakistan (US$ 16.4 million), Myanmar (US$ 13.2 million), China (US$ 12.4 million), Tajikistan (US$ 6.3 million) and Kyrgyzstan (US$ 4.3 million). The disbursements to Tajikistan and Kyrgyzstan were the largest amounts in the European Region-specifically targeted at addressing MDR-TB.

Disbursements to countries, first eight months of 2013

<table>
<thead>
<tr>
<th></th>
<th>TOTAL FUNDING ENVELOPE</th>
<th>DISBURSED TO COUNTRIES IN THE FIRST EIGHT MONTHS OF 2013</th>
<th>% OF RESPECTIVE PIPELINES</th>
</tr>
</thead>
<tbody>
<tr>
<td>TB</td>
<td>1.96</td>
<td>0.402</td>
<td>21%</td>
</tr>
<tr>
<td>Malaria</td>
<td>2.68</td>
<td>0.553</td>
<td>21%</td>
</tr>
<tr>
<td>HIV</td>
<td>5.67</td>
<td>1.116</td>
<td>22%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>10.3</td>
<td>2.071</td>
<td>20%</td>
</tr>
</tbody>
</table>

At the end of 2012, the Global Fund announced that there was an existing funding envelope of US$ 10.3 billion for all three diseases for 2013-14, of which US$ 1.96 billion was earmarked for TB (table).

TBTEAM partners are monitoring the disbursements of grants to countries as well as providing technical assistance and guidance to facilitate implementation, in collaboration with partners.

TBTEAM in action: July-September 2013

Over the past 3 months, the TBTEAM Secretariat organized teleconferences to discuss preparations for phase 2 renewals, programme reviews, on-going grant implementation, impending drug-stock outs, and/or national strategic planning in the below countries. Partners involved in the discussions included national TB programmes, the Global Fund, USAID, Global Fund Principal Recipients, technical partners, and WHO country and regional offices. The countries covered in teleconference discussions included: Angola, Central African Republic, Senegal, Côte d’Ivoire, Uganda, Georgia, Malawi, Morocco, Niger, Nigeria, Kenya, Djibouti, Ethiopia, Mauritania and Namibia.

In addition to direct follow-up from Geneva, the TBTEAM Secretariat provided data to technical partners on Global Fund TB grant ratings and made available management letters to provide entry points for grant follow up in country. TBTEAM partners also facilitated discussions for planning and participated in reviews that occurred during this period:

- Burundi: 29 July – 9 August
- Central African Republic: 4-31 July
- Ethiopia: 20 August – 5 September
- Liberia: 29 July- 9 August
- Uganda: 4-14 September
- Tajikistan: 15-23 July
- Nepal: 23 June – 1 July
- Thailand: 13-27 August
- Philippines: 26 August – 6 September

All these activities complement the ongoing efforts of technical partners based in countries and regions to ensure that TB grants are effectively implemented.

Overview

Recent Board approval for Phase 2 renewals and interim funding for TB

This year so far, US$ 2.46 billion has been approved in phase 2 renewals and interim funding for the three diseases by the Global Fund Board. US$ 534 million of the total was allocated for 34 TB grants; this includes US$ 91.2 million approved for 13 TB grants in 10 countries in the past two months.

The countries whose TB programs will be benefitting from this include,

- Indonesia (US$ 37.4 million)
  A phase 2 grant and 1.2 million of interim funding will ensure MDR and TB/HIV scale-up.

- Senegal (US$ 11.5 million)
  A grant renewal which includes rehabilitation of 15 laboratories, extension of community DOTS to all 76 districts and decentralization of Xpert MTB/Rif to regions.

- Belarus (US$ 9.08 million)
  The grant focuses on the expansion of M/XDR diagnosis and treatment and also includes US$0.98 million of interim funding for the procurement of the XDR-TB medicine- Linezolid.

- Laos (US$ 7.54 million)
  This phase 2 renewal includes strengthening of the laboratory network to improve case finding, programmatic management of drug resistant TB, and provision of HIV counseling and testing to 90% of TB patients.
Global Fund TB grant performance, August 2013

The latest TB grant performance scores from the Global Fund are presented in the graph below. Of the 127 TB grants, 81% are performing above average.

24 grants across 21 countries have a B2 rating, and one grant – Burkina Faso has recently received a C rating (related to finance issues). TBTEAM is reaching out to partners in these countries as well as to WHO staff stationed there/in the region, to help improve performance.

Grant ratings are a useful tool to monitor performance and take early action. Falling grant ratings can be an early indication of a grant getting into difficulty and grants with a B2, or C performance ratings suggest the need for urgent consideration of additional support needs for the grant.

Mongolia (US$ 7.01 million)
Procurement of second-line drugs and diagnostic tools and reagents, improved patient support and monitoring, human resources and training.

Zimbabwe (US$ 4.94 million)
Interim funding earmarked for a prevalence survey, a drug resistance survey and programmatic expansion of MDR-TB. Additional TB/HIV activities have been programmed into the HIV grant.

In addition to the above, funding was approved for Guinea (US$ 4.26 million), Bangladesh (US$ 3.99 million), Zambia (US$ 3 million) and Honduras (US$ 2.38 million).

TBTEAM partners have supported these country TB applications for funding, and will continue assisting national TB programmes to ensure effective implementation.

Contact: tbteam@who.int

Follow us

If you no longer wish to receive these emails, please reply to this message with “Unsubscribe” in the subject line or simply click unsubscribe.